HIV/AIDS: Current Treatment (ART), Viral Suppression & Life Expectancy

HIV is manageable with antiretroviral therapy (ART). No cure yet, but viral suppression allows near-normal lifespan.

ART Principles

  • Combination ≥3 drugs from ≥2 classes – prevents resistance.
  • Goal: Plasma HIV RNA <50 copies/mL (undetectable) within 3–6 months.
  • U=U: Undetectable = Untransmittable (sexual transmission).

Preferred Initial Regimens (DHHS / WHO)

  • Integrase inhibitor (INSTI) + 2 NRTIs:
    • Bictegravir/TAF/FTC (Biktarvy) – single tablet, once daily, few interactions.
    • Dolutegravir + TAF/FTC or TDF/FTC.
    • Raltegravir + TAF/FTC (twice daily).
  • Avoid NNRTI-based (efavirenz) due to side effects/resistance.

Monitoring

  • Viral load q3–4 mo (suppressed) → q6 mo.
  • CD4 count q3–6 mo (if >500, optional).
  • Renal, hepatic, lipid, glucose, bone density (TAF better than TDF).

Complications of Untreated/Unsuppressed HIV

  • AIDS-defining illnesses (opportunistic infections, malignancies).
  • Chronic inflammation → cardiovascular, renal, hepatic, neurocognitive, bone disease.

Prevention

  • PrEP (TDF/FTC or TAF/FTC) – >99% effective for sexual transmission.
  • PEP (72 hr post-exposure).
  • TasP (Treatment as Prevention) – U=U.

With early ART, life expectancy approaches general population. Adherence is lifelong.

HIV & AIDS - Related Articles